PR Newswire

The newsfeed available here is provided by our content partner PR Newswire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 76
6.301,18 S&P · 19,08 Vola-Index · 118.533,91 BTC · 1,16252 EURUSD
System-State: Number of processed items 111.896 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
PR Newswire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
State: 20.07.2025 | 4PM
Mon, 16.06.2025       ADC Therapeutics
CH0499880968

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69%

CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment

ZYNLONTA was generally well tolerated and safety was consistent with known profile

LAUSANNE, Switzerland, June 16, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20. These data will be made available online beginning on Wednesday, June 18, at 8:30 a.m. CEST. The single-arm, open-label, study is led by Izidore S. Lossos, MD, Chief, Division of Hematology Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Read More
ADC Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Hims & Hers Health
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
© PR Newswire
PepGen
PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit
© PR Newswire
3D Systems
DDD Investors Have Opportunity to Lead 3D Systems Corporation Securities Fraud Lawsuit
© PR Newswire
Irobot
IRBT Investors Have Opportunity to Lead iRobot Corporation Securities Fraud Lawsuit
© PR Newswire
Petco Health and Wellness
WOOF Investors Have Opportunity to Lead Petco Health and Wellness Company, Inc. Securities Fraud Lawsuit
© PR Newswire
Smoore International Holdings Limited
VAPORESSO Celebrates 10th Anniversary with Groundbreaking Event in Jakarta, Kicking Off Global Celebration
© PR Newswire
Smoore International Holdings Limited
VAPORESSO Celebrates 10th Anniversary with Groundbreaking Event in Jakarta, Kicking Off Global Celebration
© PR Newswire
Centene Corp
CNC INVESTOR NOTICE: Centene Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
© PR Newswire
Caravelle
High-Trend International Group Held Extraordinary General Meeting for Share Capital Restructure
© PR Newswire
Tempus AI
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
© PR Newswire
Hims & Hers Health
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS
© PR Newswire
Reckitt Benckiser
RECKITT BENCKISER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Reckitt Benckiser Group PLC - RBGLY
© PR Newswire
Organon & Co.
TUESDAY INVESTOR DEADLINE: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
© PR Newswire
Red Cat
INVESTOR DEADLINE TUESDAY: Red Cat Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RCAT
© PR Newswire
Centene Corp
CNC Investors with Losses in Excess of $100K Have Opportunity to Lead Centene Corporation Securities Fraud Lawsuit
© PR Newswire
Montfort Capital
Montfort Capital Announces Reinstatement of Trading on TSXV
© PR Newswire
Neogen
Shareholder Alert: Robbins LLP Informs Investors of the Neogen Corporation Securities Fraud Class Action Lawsuit
© PR Newswire
Chevron
Block Set to Join S&P 500
© PR Newswire
Portland General Electric
Portland General Electric declares dividend
© PR Newswire
Centene Corp
NYSE: CNC: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Centene Corporation
© PR Newswire
Sarepta Therapeutics
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
© PR Newswire
Sarepta Therapeutics
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
© PR Newswire
Semler Scientific
Rosen Law Firm Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLR
© PR Newswire
Servotronics
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: INFA, GSRT, BGSF, and SVT
© PR Newswire
Blueprint Medicines
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD
© PR Newswire

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.